Mesoblast hits recruitment milestone in pivotal Phase 3 chronic back pain trial
Mesoblast (NASDAQ:MESO) announced a significant clinical milestone on Wednesday, April 29, 2026, confirming that its pivotal Phase 3 trial (MSB-DR004) for rexlemestrocel-L has successfully met its patient recruitment target.










